The safety and efficacy of recombinant human adenovirus 5 injection (H101) intraperitoneal administration combined with tislelizumab and platinum, fluorouracil-based drugs in the treatment of gastric
4 hours ago
- #oncolytic-viruses
- #peritoneal-metastasis
- #gastric-cancer
- Study evaluates safety and efficacy of intraperitoneal H101 combined with tislelizumab and XELOX for gastric cancer with peritoneal metastasis.
- 20 patients will receive H101, tislelizumab (200 mg, Q3W), and XELOX (oxaliplatin and capecitabine).
- Primary endpoints: safety profile and 1-year overall survival (OS) rate (target ~70%).
- Secondary endpoints: progression-free survival (PFS), radiological response (RECIST 1.1), ascites volume, and Peritoneal Carcinomatosis Index (PCI).
- Aims to provide preliminary evidence for a multimodal approach in high-risk patients with limited treatment options.
- Clinical trial registration: chiCTR2500107607.